Endotoxin contamination: A key element in the interpretation of nanosafety studies

Nanomedicine

Volumn 11, Issue 3, 2016, Pages 269-287

  Li, Yang ^a   Boraschi, Diana ^a  

^a INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

Author keywords

endotoxin contamination; endotoxin elimination; LAL assay; nanomaterials; nanosafety

Indexed keywords

ENDOTOXIN; NANOPARTICLE;

BIOLOGICAL ACTIVITY; CONTAMINATION; ENDOTOXIN DETECTION; EXTRACTION AND EXTRACTS; GEL FILTRATION CHROMATOGRAPHY; HUMAN; ION EXCHANGE CHROMATOGRAPHY; MEASUREMENT; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TWO PHASE EXTRACTION; ULTRAFILTRATION; METABOLISM; NANOTECHNOLOGY; SAFETY;

ENDOTOXINS; NANOTECHNOLOGY; SAFETY MANAGEMENT;

EID: 84956907526     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.196     Document Type: Review

References (112)

1. Yazdi AS, Guarda G, Riteau N et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1 and IL-1. Proc. Natl Acad. Sci. USA 107(45), 19449-19454 (2010).
2. Hussain S, Boland S, Baeza-Squiban A et al. Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount. Toxicology 260(1), 142-149 (2009).
3. Gosens I, Post JA, De La Fonteyne L et al. Impact of agglomeration state of nano-and submicron sized gold particles on pulmonary inflammation. Part. Fibre Toxicol. 7(1), 3-7 (2010).
4. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat. Nanotech. 4(7), 411-414 (2009).
5. Zolnik BS, González-Fernández Á, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology 151(2), 458-465 (2010).
6. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 42(2), 145-151 (2008).
7. Murphy KM, Travers P, Walport M. Janeway's Immunobiology. Garland Science, NY, USA, 7, (2012).
8. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20(1), 197-216 (2002).
9. Oostingh GJ, Casals E, Italiani P et al. Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part. Fibre Toxicol. 8(1), 8 (2011).
10. Liu AH. Endotoxin exposure in allergy and asthma: reconciling a paradox. J. Allergy Clin. Immunol. 109(3), 379-392 (2002).
11. Perros F, Lambrecht BN, Hammad H. TLR4 signalling in pulmonary stromal cells is critical for inflammation and immunity in the airways. Respir. Res. 12(1), 125 (2011).
12. Rylander R. Review: endotoxin in the environment-exposure and effects. J. Endotoxin Res. 8(4), 241-252 (2002).
13. Jacobs RR. Airborne endotoxins: An association with occupational lung disease. Appl. Ind. Hyg. 4(2), 50-56 (1989).
14. Schwartz DA. Does inhalation of endotoxin cause asthma? Am. J. Respir. Crit. Care Med. 163(2), 305-306 (2001).
15. Michel O, Kips J, Duchateau J et al. Severity of asthma is related to endotoxin in house dust. Am. J. Respir. Crit. Care Med. 154(6), 1641-1646 (1996).
16. Park JH, Gold DR, Spiegelman DL, Burge HA, Milton DK. House dust endotoxin and wheeze in the first year of life. Am. J. Respir. Crit. Care Med. 163(2), 322-328 (2001).
17. Danner RL, Elin R, Hosseini J, Wesley R, Reilly J, Parillo J. Endotoxemia in human septic shock. Chest 99(1), 169-175 (1991).
18. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7), 1761-1772 (2007).
19. Malyala P, Singh M. Endotoxin limits in formulations for preclinical research. J. Pharm. Sci. 97(6), 2041-2044 (2008).
20. Gorbet MB, Sefton MV. Endotoxin: the uninvited guest. Biomaterials 26(34), 6811-6817 (2005).
21. Sandle T. A comparative study of different methods for endotoxin destruction. Am. Pharmaceut. Rev. 16(6), 15-17 (2013).
22. Vallhov H, Qin J, Johansson SM et al. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett. 6(8), 1682-1686 (2006).
23. Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev. 61(6), 438-456 (2009).
24. Lieder R, Petersen PH, Sigurjónsson OE. Endotoxins-the invisible companion in biomaterials research. Tissue Eng. Part B Rev. 19(5), 391-402 (2013).
25. Darkow R, Groth T, Albrecht W, Lützow K, Paul D. Functionalized nanoparticles for endotoxin binding in aqueous solutions. Biomaterials 20(14), 1277-1283 (1999).
26. Karl DW, Magnusson JC, Carr PW, Flickinger MC. Preliminary assessment of removal of pyrogenic lipopolysaccharides with colloidal zirconia adsorbents. Enzyme Microb. Technol. 13(9), 708-715 (1991).
27. Bromberg L, Chang EP, Alvarez-Lorenzo C, Magarinos B, Concheiro A, Hatton TA. Binding of functionalized paramagnetic nanoparticles to bacterial lipopolysaccharides and DNA. Langmuir 26(11), 8829-8835 (2010).
28. Peula-Garca J, Molina-Bolivar J, Velasco J, Rojas A, Galisteo-González F. Interaction of bacterial endotoxine (lipopolysaccharide) with latex particles: Application to latex agglutination immunoassays. J. Colloid Interface Sci. 245(2), 230-236 (2002).
29. Jiang W, Ghosh S, Song L, Vachet RW, Xing B. Effect of Al2O3 nanoparticles on bacterial membrane amphiphilic biomolecules. Colloids Surf. B Biointerfaces 102, 292-299 (2013).
30. Li Y, Tran N, Puntes VF, Boraschi D. Bacterial endotoxin binds to the surface of gold nanoparticles and triggers inflammation. Presented at: 7th International Nanotoxicology Congress Nanotox 2014. Antalya, Turkey, 23-26 April 2014.
31. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081), 237-241 (2006).
32. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320(5876), 674-677 (2008).
33. Van De Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1 and IL-18 processing during infection. Trends Immunol. 32(3), 110-116 (2011).
34. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J. Biol. Chem. 287(43), 36617-36622 (2012).
35. Ghonime MG, Shamaa OR, Das S et al. Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function. J. Immunol. 192(8), 3881-3888 (2014).
36. Fernandes-Alnemri T, Kang S, Anderson C, Sagara J, Fitzgerald KA, Alnemri ES. Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome. J. Immunol. 191(8), 3995-3999 (2013).
37. Qu G, Liu S, Zhang S et al. Graphene oxide induces toll-like receptor 4 (TLR4)-dependent necrosis in macrophages. ACS Nano 7(7), 5732-5745 (2013).
38. Chen G-Y, Yang H-J, Lu C-H et al. Simultaneous induction of autophagy and toll-like receptor signaling pathways by graphene oxide. Biomaterials 33(27), 6559-6569 (2012).
39. Bastús NG, Sánchez-Tilló E, Pujals S et al. Peptides conjugated to gold nanoparticles induce macrophage activation. Mol. Immunol. 46(4), 743-748 (2009).
40. Chen Z, Liu Y, Sun B et al. Polyhydroxylated metallofullerenols stimulate IL-1 secretion of macrophage through TLRs/MyD88/NF-B pathway and NLRP3 inflammasome activation. Small 10(12), 2362-2372 (2014).
41. Hornung V, Bauernfeind F, Halle A et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9(8), 847-856 (2008).
42. Baron L, Gombault A, Fanny M et al. The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine. Cell Death Dis. 6(2), e1629 (2015).
43. Cho DR, Shanbhag AS, Hong C-Y, Baran GR, Goldring SR. The role of adsorbed endotoxin in particle-induced stimulation of cytokine release. J. Orthop. Res. 20(4), 704-713 (2002).
44. Ashwood P, Thompson RP, Powell JJ. Fine particles that adsorb lipopolysaccharide via bridging calcium cations may mimic bacterial pathogenicity towards cells. Exp. Biol. Med. 232(1), 107-117 (2007).
45. Brooks R, Wimhurst J, Rushton N. Endotoxin contamination of particles produces misleading inflammatory cytokine responses from macrophages in vitro. J. Bone Joint Surg. Br. 84(2), 295-299 (2002).
46. Monn C, Becker S. Cytotoxicity and induction of proinflammatory cytokines from human monocytes exposed to fine (PM 2. 5) and coarse particles (PM 10-2. 5) in outdoor and indoor air. Toxicol. Appl. Pharmacol. 155(3), 245-252 (1999).
47. Chapekar Ms, Zaremba Tg, Kuester Rk, Hitchins Vm. Synergistic induction of tumor necrosis factor alpha by bacterial lipopolysaccharide and lipoteichoic acid in combination with polytetrafluoroethylene particles in a murine macrophage cell line RAW 264. 7. J. Biomed. Mater. Res. 31(2), 251-256 (1996).
48. Inoue K-I, Takano H, Yanagisawa R et al. Effects of airway exposure to nanoparticles on lung inflammation induced by bacterial endotoxin in mice. Environ. Health Perspect. 114(9), 1325 (2006).
49. Shi Y, Yadav S, Wang F, Wang H. Endotoxin promotes adverse effects of amorphous silica nanoparticles on lung epithelial cells in vitro. J. Toxicol. Environ. Health A 73(11), 748-756 (2010).
50. Inoue K-I, Takano H, Yanagisawa R et al. Effects of inhaled nanoparticles on acute lung injury induced by lipopolysaccharide in mice. Toxicology 238(2), 99-110 (2007).
51. Inoue K-I, Takano H, Yanagisawa R, Koike E, Shimada A. Size effects of latex nanomaterials on lung inflammation in mice. Toxicol. Appl. Pharmacol. 234(1), 68-76 (2009).
52. Inoue K, Takano H, Ohnuki M et al. Size effects of nanomaterials on lung inflammation and coagulatory disturbance. Int. J. Immunopathol. Pharmacol. 21(1), 197-206 (2008).
53. Schwab LP, Xing Z, Hasty KA, Smith RA. Titanium particles and surface-bound LPS activate different pathways in IC-21 macrophages. J. Biomed. Mater. Res. B Appl. Biomater. 79(1), 66-73 (2006).
54. Ma JS, Kim WJ, Kim JJ et al. Gold nanoparticles attenuate LPS-induced NO production through the inhibition of NF-B and IFN-/STAT1 pathways in RAW264. 7 cells. Nitric Oxide 23(3), 214-219 (2010).
55. Pereira DV, Petronilho F, Pereira HRSB et al. Effects of gold nanoparticles on endotoxin-induced uveitis in rats. Invest. Ophthalmol. Vis. Sci. 53(13), 8036-8041 (2012).
56. Rehman MU, Yoshihisa Y, Miyamoto Y, Shimizu T. The anti-inflammatory effects of platinum nanoparticles on the lipopolysaccharide-induced inflammatory response in RAW 264. 7 macrophages. Inflamm. Res. 61(11), 1177-1185 (2012).
57. Dutta D, Sundaram SK, Teeguarden JG et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol. Sci. 100(1), 303-315 (2007).
58. Liu Z, Li W, Wang F et al. Enhancement of lipopolysaccharide-induced nitric oxide and interleukin-6 production by PEGylated gold nanoparticles in RAW264. 7 cells. Nanoscale 4(22), 7135-7142 (2012).
59. Herzog F, Loza K, Balog S et al. Mimicking exposures to acute and lifetime concentrations of inhaled silver nanoparticles by two different in vitro approaches. Beilstein J. Nanotechnol. 5(1), 1357-1370 (2014).
60. Inoue K-I, Takano H, Koike E et al. Effects of pulmonary exposure to carbon nanotubes on lung and systemic inflammation with coagulatory disturbance induced by lipopolysaccharide in mice. Exp. Biol. Med. 233(12), 1583-1590 (2008).
61. Pulskamp K, Diabaté S, Krug HF. Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants. Toxicol. Lett. 168(1), 58-74 (2007).
62. Lucarelli M, Gatti AM, Savarino G et al. Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. Eur. Cytokine Netw. 15(4), 339-346 (2004).
63. US FDA. Guideline on validation of the Limulus Amebocyte Lysate test as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices. U. S. Department of Health and Human Services, Public Health Service, Food and Drug Administration (1987). www. gmpua. com/Validation/Method/LAL
64. USP. Chapter 85: Bacterial endotoxins test. In: United States Pharmacopeia. United States Pharmacopeial Convention, MD, USA (2005).
65. FDA, CBER, CMV, CDRH, ORA. Guidance for industry. Pyrogen and endotoxins testing: questions and answers (2012). www. fda. gov/Drugs/GuidanceCompliance
66. Li Y, Italiani P, Casals E, Tran N, Puntes VF, Boraschi D. Optimising the use of commercial LAL assays for the analysis of endotoxin contamination in metal colloids and metal oxide nanoparticles. Nanotoxicology 9(4), 462-473 (2015).
67. ISO. ISO/FDIS 29701: Nanotechnologies-endotoxin test on nanomaterial samples for in vitro systems-Limulus amebocyte lysate (LAL) test (2010). www. iso. org/iso/iso-catalogue/catalogue-tc/catalogue
68. Dobrovolskaia MA, Neun BW N, Clogston JD, Ding H, Ljubimova J, McNeil SE. Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine 5(4), 555-562 (2010).
69. Dobrovolskaia MA, Neun BW, Clogston JD, Grossman JH, Mcneil SE. Choice of method for endotoxin detection depends on nanoformulation. Nanomedicine 9(12), 1847-1856 (2014).
70. Smulders S, Kaiser JP, Zuin S et al. Contamination of nanoparticles by endotoxin: evaluation of different test methods. Part. Fibre Toxicol. 9(1), 41 (2012).
71. Kucki M, Cavelius C, Kraegeloh A. Interference of silica nanoparticles with the traditional Limulus amebocyte lysate gel clot assay. Innate Immun. 20(3), 327-336 (2014).
72. Twohy CW, Duran AP, Munson TE. Endotoxin contamination of parenteral drugs and radiopharmaceuticals as determined by the limulus amebocyte lysate method. J. Parenter Sci. Technol. 38(5), 190-201 (1984).
73. Spaan S, Heederik DJ, Thorne PS, Wouters IM. Optimization of airborne endotoxin exposure assessment: effects of filter type, transport conditions, extraction solutions, and storage of samples and extracts. Appl. Environ. Microbiol. 73(19), 6134-6143 (2007).
74. Douwes J, Versloot P, Hollander A, Heederik D, Doekes G. Influence of various dust sampling and extraction methods on the measurement of airborne endotoxin. Appl. Environ. Microbiol. 61(5), 1763-1769 (1995).
75. Esch RK, Han L, Foarde KK, Ensor DS. Endotoxin contamination of engineered nanomaterials. Nanotoxicology 4(1), 73-83 (2010).
76. Ragab AA, Van De Motter R, Lavish SA et al. Measurement and removal of adherent endotoxin from titanium particles and implant surfaces. J. Orthop. Res. 17(6), 803-809 (1999).
77. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J. Immunol. 187(5), 2626-2631 (2011).
78. Mano SS, Kanehira K, Taniguchi A. Comparison of cellular uptake and inflammatory response via toll-like receptor 4 to lipopolysaccharide and titanium dioxide nanoparticles. Int. J. Mol. Sci. 14(7), 13154-13170 (2013).
79. Mano SS, Kanehira K, Sonezaki S, Taniguchi A. Toll-like receptor 4 is involved in titanium dioxide nanoparticle incorporation into cells. Sci. Adv. Mater. 6(7), 1562-1568 (2014).
80. Cui Y, Liu H, Zhou M et al. Signaling pathway of inflammatory responses in the mouse liver caused by TiO2 nanoparticles. J. Biomed. Mater. Res. A 96(1), 221-229 (2011).
81. Özcan I, Bouchemal K, Segura-Sánchez F, Abac O Özer Ö, Güneri T. Effects of sterilization techniques on the PEGylated poly (benzyl-l-glutamate)(PBLG) nanoparticles. Acta Pharm. Sci. 51, 211-218 (2009).
82. Masson V, Maurin F, Fessi H, Devissaguet J. Influence of sterilization processes on poly (e-caprolactone) nanospheres. Biomaterials 18(4), 327-335 (1997).
83. Godara A, Raabe D, Green S. The influence of sterilization processes on the micromechanical properties of carbon fiberreinforced PEEK composites for bone implant applications. Acta Biomater. 3(2), 209-220 (2007).
84. Zheng J, Clogston J, Patri A, Dobrovolskaia M, Mcneil S. Sterilization of silver nanoparticles using standard gamma irradiation procedure affects particle integrity and biocompatibility. J. Nanomed. Nanotechnol. S5, 2 (2011).
85. França Á, Pelaz B, Moros M et al. Sterilization matters: consequences of different sterilization techniques on gold nanoparticles. Small 6(1), 89-95 (2010).
86. Vetten MA, Yah CS, Singh T, Gulumian M. Challenges facing sterilization and depyrogenation of nanoparticles: effects on structural stability and biomedical applications. Nanomed. Nanotech. Biol. Med. 10(7), 1391-1399 (2014).
87. Petsch D, Anspach FB. Endotoxin removal from protein solutions. J. Biotechnol. 76(2), 97-119 (2000).
88. Magalhães PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna T, Pessoa A Jr. Methods of endotoxin removal from biological preparations: A review. J. Pharm. Pharm. Sci. 10(3), 388-404 (2007).
89. Serdakowski London A, Kerins B, Tschantz WR, Mackay K. Endotoxin removal and prevention for preclinical biologics production. Biotechnol. J. 7(12), 1509-1516 (2012).
90. Williams KL. Endotoxins: Pyrogens, Lal Testing and Depyrogenation. Informa Healthcare, NY, USA, 167, (2007).
91. Sweadner KJ, Forte M, Nelsen L. Filtration removal of endotoxin (pyrogens) in solution in different states of aggregation. Appl. Environ. Microbiol. 34(4), 382-385 (1977).
92. Sawada Y, Fujii R, Igami I, Kawai A, Kamiki T, Niwa M. Removal of endotoxin from water by microfiltration through a microporous polyethylene hollow-fiber membrane. Appl. Environ. Microbiol. 51(4), 813-820 (1986).
93. Madaeni S. The application of membrane technology for water disinfection. Water Res. 33(2), 301-308 (1999).
94. Diogo M, Queiroz J, Prazeres D. Chromatography of plasmid DNA. J. Chromatogr. A 1069(1), 3-22 (2005).
95. London AS, Mackay K, Lihon M, He Y, Alabi BR. Gel filtration chromatography as a method for removing bacterial endotoxin from antibody preparations. Biotechnol. Prog. 30(6), 1497-1501 (2014).
96. Aida Y, Pabst MJ. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J. Immunol. Methods 132(2), 191-195 (1990).
97. Damais C, Jupin C, Parant M, Chedid L. Induction of human interleukin-1 production by polymyxin B. J. Immunol. Methods 101(1), 51-56 (1987).
98. Lerouge S, Wertheimer M, L'H Y. Plasma sterilization: A review of parameters, mechanisms, and limitations. Plasmas Polym. 6(3), 175-188 (2001).
99. Rossi F, Kylian O, Rauscher H, Hasiwa M, Gilliland D. Low pressure plasma discharges for the sterilization and decontamination of surfaces. New J. Phys. 11(11), 115017 (2009).
100. Rossi F, Kylián O, Hasiwa M. Decontamination of surfaces by low pressure plasma discharges. Plasma Process. Polym. 3(6-7), 431-442 (2006).
101. Kylián O, Hasiwa M, Rossi F. Plasma based depyrogenization. Plasma Process. Polym. 3(3), 272-275 (2006).
102. Hasiwa M, Kylián O, Hartung T, Rossi F. Removal of immune-stimulatory components from surfaces by plasma discharges. Innate Immun. 14(2), 89-97 (2008).
103. Kylian O, Hasiwa M, Rossi F. Effect of low-pressure microwave discharges on pyrogen bioactivity. IEEE T Plasma Sci. 34(6), 2606-2610 (2006).
104. Matthews JB, Besong AA, Green TR et al. Evaluation of the response of primary human peripheral blood mononuclear phagocytes to challenge with in vitro generated clinically relevant UHMWPE particles of known size and dose. J. Biomed. Mater. Res. 52(2), 296-307 (2000).
105. Papageorgiou I, Brown C, Schins R et al. The effect of nanoand micron-sized particles of cobalt-chromium alloy on human fibroblasts in vitro. Biomaterials 28(19), 2946-2958 (2007).
106. Grandjean-Laquerriere A, Laquerriere P, Laurent-Maquin D, Guenounou M, Phillips TM. The effect of the physical characteristics of hydroxyapatite particles on human monocytes IL-18 production in vitro. Biomaterials 25(28), 5921-5927 (2004).
107. Grandjean-Laquerriere A, Laquerriere P, Guenounou M, Laurent-Maquin D, Phillips TM. Importance of the surface area ratio on cytokines production by human monocytes in vitro induced by various hydroxyapatite particles. Biomaterials 26(15), 2361-2369 (2005).
108. Grandjean-Laquerriere A, Tabary O, Jacquot J et al. Involvement of toll-like receptor 4 in the inflammatory reaction induced by hydroxyapatite particles. Biomaterials 28(3), 400-404 (2007).
109. Hitchins V, Merritt K. Decontaminating particles exposed to bacterial endotoxin (LPS). J. Biomed. Mater. Res. 46(3), 434-437 (1999).
110. Herrmann IK, Urner M, Graf S et al. Endotoxin removal by magnetic separation-based blood purification. Adv. Healthc. Mater. 2(6), 829-835 (2013).
111. Lee JJ, Jeong KJ, Hashimoto M et al. Synthetic ligand-coated magnetic nanoparticles for microfluidic bacterial separation from blood. Nano Lett. 14(1), 1-5 (2014).
112. Hankin S, Boraschi D, Duschl A, Lehr C-M, Lichtenbeld H. Towards nanotechnology regulation-publish the unpublishable. Nano Today 6(3), 228-231 (2011).